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Anti-nogo-A antibodies prevent 
vascular leakage and act as pro-
angiogenic factors following stroke
Ruslan Rust  1,2*, Rebecca Z. Weber3, Lisa Grönnert1, Geertje Mulders2, Michael A. Maurer1, 
Anna-Sophie Hofer1,2, Andrea M. Sartori  1,2 & Martin E. Schwab1,2
Angiogenesis is a key restorative process following stroke but has also been linked to increased vascular 
permeability and blood brain barrier (BBB) disruption. Previous pre-clinical approaches primarily 
focused on the administration of vascular endothelial growth factor (VEGF) to promote vascular repair 
after stroke. Although shown to improve angiogenesis and functional recovery from stroke, VEGF 
increased the risk of blood brain barrier disruption and bleedings to such an extent that its clinical use 
is contraindicated. As an alternative strategy, antibodies against the neurite growth inhibitory factor 
Nogo-A have recently been shown to enhance vascular regeneration in the ischemic central nervous 
system (CNS); however, their effect on vascular permeability is unknown. Here, we demonstrate that 
antibody-mediated Nogo-A neutralization following stroke has strong pro-angiogenic effects but does 
not increase vascular permeability as opposed to VEGF. Moreover, VEGF-induced vascular permeability 
was partially prevented when VEGF was co-administered with anti-Nogo-A antibodies. This study may 
provide a novel therapeutic strategy for vascular repair and maturation in the ischemic brain.
Ischemic stroke results from focal cerebral ischemia due to occlusion of a cerebral blood vessel. At the core of 
the stroke, affected brain regions lose their supply of oxygen and glucose with immediate disturbance of func-
tion followed by necrotic cell death within hours. Surrounding the core is a zone of reduced blood flow with 
partial blockade of vessels, the ischemic border zone. Prolonged ischemia leads to tissue damage in this zone; 
however, restoration of blood supply by angiogenesis, the formation of new blood vessels, may prevent some of 
these degenerative events1,2. Preclinical research has linked therapeutic enhancement of angiogenesis through 
vascular growth factors to improved neurological outcomes, but these therapies have failed to be translated into 
clinical application due to safety concerns3,4. In parallel to inducing angiogenesis, vascular growth factors have 
been shown to trigger a cascade of aggravating events including increased vascular permeability and blood brain 
barrier breakdown as well as an increased risk of bleedings from immature, unstable vessels (hemorrhagic trans-
formation)5–8. VEGF has been shown to disrupt the barrier function of the vessel endothelium through the pro-
motion of pericyte detachment and degradation of tight junction proteins including claudins8 and cadherins9. 
Moreover, VEGF delivery appears to have a narrow therapeutic window due to dosing and a half life time of 
only several minutes in vivo10,11. Thus, alternative strategies are required without the risk of vascular leakage and 
bleeding.
Recently, the neurite outgrowth inhibitor Nogo-A, a membrane protein expressed by oligodendrocytes and 
subpopulations of neurons, has been shown to limit vascular growth in development12 and after CNS ischemia13. 
Its neutralization improved vascular repair in the ischemic border zone of cerebral strokes as well as functional 
outcome.
Here, we hypothesized that Nogo-A might represent a safe pro-angiogenic therapeutic target that does not 
increase vascular permeability and BBB integrity in contrast to VEGF. We identified anti-Nogo-A antibod-
ies as promising new reagents to enhance vascular repair and maturation. In particular, we demonstrate that 
anti-Nogo-A antibodies (1) have similar pro-angiogenic effects as local VEGF treatment (2) do not increase 
vascular permeability in the peri-infarction regions, (3) partially reverse the VEGF induced blood vessel leakage 
when co-administrated.
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Results
Blood-brain-barrier permeability is elevated in peri-infarct regions following ischemic stroke. 
A significant hallmark of the brain tissue in the peri-infarct regions is the dysfunction of the BBB resulting in 
edema and the penetration of serum proteins into the CNS parenchyma. Yet the role of disturbed vascular per-
meability in stroke progression is not clear. We induced a photothrombotic stroke in the sensorimotor cortex 
of adult mice and analyzed vascular permeability in the acute (1 day post injury (dpi)), subacute (7 dpi), and 
chronic (21 dpi) phase by Evans Blue (EB) extravasation in micro-dissected lysates of different brain regions 
(Fig. 1A,B). Moreover, histology of coronal cortical sections was performed in a subgroup of animals that were 
either intact or at 7 dpi in the peri-infarct regions (Suppl. Figure S1). In the intact animals, EB was entirely con-
fined to the vessel system in the CNS and could be fully removed by perfusion (Fig. 1C). EB/albumin concen-
trations in lysed brain tissue could be detected (at Ex: 620/Em: 680) with a sensitivity of 0.006 ng/mg (LOD), or 
respectively 0.019 ng (LOQ) per mg brain lysate (Fig. 1D). Analysis of EB extravasation in the peri-infarct region 
revealed a disrupted BBB throughout the time course (1 dpi: 42.91 ± 7.80 ng/mg, 7 dpi: 34.01 ± 14.77 ng/mg, 21 
dpi: 31.54 ± 16.06 ng/mg tissue compared to uninjured cortices 5.32 ± 0.01 ng/mg, all p < 0.001, Fig. 1C,E). With 
progressing time the intragroup variability increased, suggesting a partial restoration of the BBB in individual 
animals. Interestingly, acutely after stroke, a subset of animals showed increased EB concentrations also in the 
Figure 1. Temporal evolution of blood brain barrier disruption in brain lysates. (A) Schematic representation 
of the experimental timeline and the dissected brain regions for EB measurement. (B) Representative stroked 
brain with incorporated EB dye as RGB, heatmap and binarized image, scale bar: 5 mm. (C) Microscope images 
showing EB dye accumulation in non-perfused vasculature (CD31), its absence in intact perfused vessels, 
and its leakage into the injured peri-infarct parenchyma. Scale bar 100 um. (D) Absorbance spectrum and 
spectroscopic detection limit shown by EB dilution curve. (E) Quantitative evaluation of EB signal intensities 
in brain lysates of different regions from day 1 to day 21 after stroke including the injured and contralesional 
cortex, hippocampus, cerebellum and visual cortex. Isch cx; ischemic cortex, contra cx; contralesional cortex, 
hp; hippocampus, cb; cerebellum, vcx, visual cortex. EB; Evans Blue, ibz; ischemic border zone.
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contralesional cortex (17.04 ± 11.92 ng/mg tissue, p < 0.001) and in both hippocampi (left: 8.63 ± 3.09 ng/mg, 
p = 0.002, right: 8.97 ± 5.49 ng/mg, p = 0.027) compared to corresponding regions in uninjured animals, sug-
gesting the extension of the BBB damaging effects into the contralesional hemisphere (Fig. 1E). Little to no signal 
(<10 ng/mg tissue) was detected in visual cortex and cerebellum through the time course compared to uninjured 
controls (p > 0.05) (Fig. 1E).
These results show a massive breakdown of the BBB from d.1 to d.21 after stroke, which is mostly restricted, 
however to the peri-infarct cortex in addition to the stroke core.
Antibody-mediated neutralization of Nogo-A and vascular endothelial growth factor applica-
tion display comparable angiogenic effects in the ischemic brain. BBB damage with subsequent 
edema and inflammation following stroke and other cerebrovascular diseases result in neuronal damage and 
prolonged loss of brain functions14–17. Therapeutics like VEGF, which enhance vessel growth but also lead to BBB 
opening therefore have only limited translational value5,7,9. We evaluated an alternative pro-angiogenic strategy 
by blocking the inhibitory factor Nogo-A with antibodies18 and studied the effects of this treatment on the BBB in 
the peri-infarct region surrounding the stroke.
Initially, we compared the pro-angiogenic effects of a 7 day intraventricular infusion of either VEGF, or 
anti-Nogo-A antibody (α-Ng-Ab), or a combined administration of VEGF and α-Ng-Ab (Comb), or a) con-
trol antibody (Ctrl-Ab) (Fig. 2A). In line with previous observations, Ctrl-Ab receiving animals showed a large 
drop in vessel density, branch number and vessel length within the peri-infarct region up to 300 µm from the 
border of the stroke core compared to the contralesional hemisphere18 (Fig. 2D). In contrast, the VEGF, the 
α-Ng-Ab, and the Comb groups displayed considerable improvement in vascular repair (Fig. 2B-D). The vas-
cular area fraction in the region around the stroke core was increased more than 1.5-fold (VEGF: 0.134 ± 0.019, 
p = 0.004; a-Ng-Ab: 0.132 ± 0.039, p = 0.012; Comb: 0.143 ± 0.023, p = 0.001) compared to controls (Ctrl-Ab: 
0.078 ± 0.019). The number of branches per mm2 increased by 114% (VEGF, 371.84 ± 66.67, p = 0.003), 
156% (α-Ng-Ab, 443.69 ± 127.91, p < 0.001), and by 168% (Comb, 464.97 ± 85.39, p < 0.001) compared to 
control (Ctrl-Ab:173.20 ± 71.04) and the length of blood vessel segments per mm2 increased by 53% (VEGF, 
44.44 ± 6.29 mm, p = 0.004), 53% (α-Ng-Ab, 44.22 ± 6.44 mm, p = 0.008) and by 54% (Comb: 44.70 ± 7.12 mm, 
p = 0.003) compared to control (Ctrl-Ab: 28.95 ± 7.89 mm). Nearest vessel neighbor distance (NND) and varia-
bility in the distribution of the blood vessels revealed no significant differences (Fig. 2D). The combined treatment 
did not show any beneficial angiogenic effects compared to either VEGF (area fraction: +6%, branching: +25%, 
length: +0.5%, NND: +4%, all p > 0.05) or a-Ng-A Ab (area fraction: +8%, branching: +5%, length: +1%, NND: 
+3%, all p > 0.05) alone.
Importantly, no differences in total stroke volumes have been observed between the groups (Suppl. Figure S2).
In order to identify newly formed blood vessels, the nucleotide analogue, 5-ethynyl–2′-deoxyuridine (EdU) 
was given daily on days 6–8 after ischemia (around the peak of post-stroke angiogenesis19). Nuclei of CD31+ 
vascular endothelial cells that incorporated EdU were identified as newly formed after injury and quantified 
(Fig. 2 E, F). The number of EdU+/CD31+ cells per mm2 was significantly increased in the peri-infarct region of 
animals in treated with VEGF:109.84 ± 24.73, p < 0.001, α-Ng-Ab: 83.78 ± 22.31, p = 0.045 or the Comb group: 
84.65 ± 15.50, p = 0.023) compared to control antibody treated mice (49.58 ± 15.87, Fig. 2G).
These data demonstrate a pro-angiogenic effect of α-Ng-Ab comparable to the effect exerted by VEGF. The 
combined treatment yielded equivalent results in terms of vascular repair and formation of new vessels.
Nogo-A neutralization does not increase vascular permeability and counteracts VEGF-induced 
leakage in the peri-infarct cortex. To examine the effects of VEGF and anti-Nogo-A treatment on 
BBB leakage, EB was systemically administered at 9 dpi; 24 hours prior to perfusion. Whole stroke brains were 
imaged and levels of tissue-bound EB were determined by signal intensity measurements. A strong EB signal 
was observed within the stroke core. In the peri-infarct zone the EB signal gradually decreased as distance from 
the stroke core in all experimental groups (Ctrl-Ab, VEGF, α-Ng-Ab, Comb; Fig. 3A). Quantitatively, levels of 
vascular leakage were assessed by measuring the circumference (circ.) and the area of signal intensities in the 
core zone (defined as >2x the intensity measured in the contralateral hemisphere) and in the peri-infarct regions 
(>1.5x intensity of the contralesional side. All groups showed comparable levels of core area in mm2 (Ctrl Ab: 
7.74 ± 3.51, VEGF: 8.86 ± 3.24, α-Ng-Ab: 8.61 ± 3.81; Comb: 9.21 ± 3.95, all p > 0.88) and core circumference 
in mm (Ctrl Ab: 11.55 ± 2.43; VEGF: 11.70 ± 2.30; α-Ng-Ab: 11.38 ± 2.65; Comb: 11.83 ± 2.58, all p > 0.98) 
(Fig. 3B). However, animals treated with VEGF showed a markedly larger area of elevated extravascular EB levels 
within the peri-infarct region compared to the control cohort (Fig. 3C). Both the area (control: 11.82 ± 4.98; 
VEGF: 23.80 ± 7.05, p = 0.006) and the circumference (control: 13.76 ± 2.36; VEGF: 18.53 ± 2.91, p = 0.017) of 
elevated extravasated EB dye were significantly increased within the peri-infarct cortical region compared to the 
control cohort. In contrast, no increase of EB extravasation area in mm2 or circumference in mm was detected 
between the control (area: 11.82 ± 4.98, circ.: 13.76 ± 2.36), the anti-Nogo-A antibody group (area: 12.89 ± 4.61, 
p = 0.99; circ.: 14.52 ± 2.55, p = 0.96) and, interestingly, also the combined VEGF and α-Ng-Ab group (area: 
16.09 ± 5.83, p = 0.56; circ.: 15.21 ± 2.57, p = 0.75, Fig. 3C).
A histological analysis of vascular permeability was performed on brain sections for the stroke core, 
peri-infarct regions and the contralesional cortex (Fig. 4A). We observed a high EB signal in the stroke core 
(0–1 mm, Fig. 4A,B). Next to the core, we often observed a characteristic drop of the signal due to a frequent 
histological artefact: disruption of the tissue between the stroke core and the remaining parts of the brain. The 
second, lower peak of the EB signal was assigned to the peri-infarct ischemic border zone. Enhanced EB signal 
was detectable up to 0.6 mm from the stroke border (IBZ, 1.5–2.1 mm). Further away from the ischemic border 
zone the EB signal approaches that of the contralesional cortex (>2.1 mm) (Fig. 4B).
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Differences between the treatment groups were assessed by calculating the area under the curve (AUC) nor-
malized to the extent of signal at the contralesional cortex of Ctrl Ab animals. The signal intensities in the stroke 
core were comparable between all treatment groups (Fig. 4C). However, VEGF-treated animals displayed signif-
icantly increased signal intensities within both more proximal (±1.5–1.8 mm distance from stroke core) (right: 
+28.41 ± 51.96%, p = 0.533, left: +68.81 ± 36.19%, p = 0.031) and distal peri-infarct regions (±1.8–2.1 mm dis-
tance from stroke core) (right: +303.46 ± 30.34%, p = 0.001; left: +126.40 ± 33.25%, p = 0.014) compared to Ctrl 
Ab treated animals. Animals receiving either anti-Nogo-A antibodies or the combined treatment did not show 
any indication of increased BBB permeability within both proximal and distal peri-infarct regions compared to 
the control. Interestingly, VEGF treated animals also revealed enhanced vascular leakage on the contralesional 
Figure 2. Vascular repair in the peri-infarct region following stroke in response to VEGF and anti-Nogo-A 
antibodies. (A) Schematic representation of the analyzed cortical region and experimental timeline in the four 
experimental groups: Ctrl-Ab (N = 6), VEGF (N = 7), α-Ng-Ab (N = 5), Combined (VEGF and α-Ng-Ab) 
(N = 7). (B) Overview of the assessed vascular parameters including the vascular area fraction (area), number 
of branch points (branches), vessel segment length (length) and nearest neighbor distance and variability 
(distance). (C) Fluorescent images of blood vessels (CD31+) in the peri-infarction region in the four treatment 
groups. Scale bar = 100 μm. (D) Quantitative evaluation of the vascular area fraction, number of branches, 
vessel segment length, nearest neighbor distance and variability in the peri-infarct region. (E) Experimental 
timeline of EdU injections. (F) Fluorescent images of newly formed blood vessels (EdU+ - pink; CD31+ - white), 
Scale bar = 50 μm. (G) Quantification of EdU+/CD31+ cells in the peri-infarct region. Data are represented 
as mean ± SD. Each dot in the plots represents one animal and significance of mean differences between the 
groups was assessed using Tukey’s HSD. Asterisks indicate significance: *P < 0.05, **P < 0.01, ***P < 0.001. 
CTX, cortex; CC corpus callosum.
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hemisphere compared to all other groups (Ctrl-Ab: +179.59 ± 10.01%, p = 0.027; α-Ng-Ab: +134.59 ± 9.54%, 
p = 0.001; Comb: + 314.60 ± 9.39%, p = 0.005) (Fig. 4C).
These results show that the pro-angiogenic effect of VEGF is accompanied by enhanced vascular leakage in 
peri-infarct regions that are associated with vascular growth as well as in non-injured CNS regions. These leak-
age effects were not observed in anti-Nogo-A treated animals and could be partially prevented in a combined 
treatment.
Nogo-A neutralization leads to the formation of a mature vascular network as opposed to 
VEGF treatment in the peri-infarct cortex. It has been previously observed that VEGF may induce a 
failure of recruiting periendothelial cells such as pericytes as well as a decrease of the function of tight junctions, 
e.g. by a drop in tight junction proteins (e.g. VE-Cadherin, ZO-1 and Claudin-5). We confirm a lower pericyte 
coverage of blood vessels in the IBZ of VEGF treated animals compared to those receiving anti-Nogo-A Ab 
(VEGF: 12.13 ± 4.97%; α-Ng-Ab: 47.50 ± 17.60%, p < 0.001, Fig. 5A-C). Moreover, the expression of tight junc-
tion proteins VE-Cadherin and ZO-1 were increased in anti-Nogo-A antibody treated animals (VE-Cadherin: 
VEGF: 9.25 ± 2.92%; α-Ng-Ab: 23.91 ± 5.03%, p = 0.007, and ZO-1: VEGF: 2.31 ± 2.35%; α-Ng-Ab: 7.71 ± 3.79, 
p = 0.01). The VEGF effects were partly reversed in the combined treatment (VE-Cadherin: Combined: 
28.59 ± 12.49%, p = 0.004, ZO-1: 4.85 ± 1.99%, p = 0.15) (Fig. 5C). No significant differences were observed 
for Claudin-5 between the groups (Ctrl: 4.95 ± 4.94%, VEGF: 6.05 ± 1.33%, α-Ng-Ab: 8.33 ± 4.95% Combined: 
10.68 ± 3.12%, p > 0.05) (Fig. 5C).
Figure 3. Vascular leakage in the peri-infarct region in response to VEGF or anti-Nogo-A antibodies in whole 
brain images. (A) Dorsal view of representative brains with extravasated EB in and around the stroke cores with 
corresponding heatmap. Scale bar: 5 mm (B) Quantitative measure of area (top) and circumference (bottom) of 
the EB leakage in the stroke core (C) and in the peri-infarct zone. Brain templates visualize local EB distribution 
from single animals in the core (green) and peri-infarct zone (purple). Data are represented as mean ± SD. Each 
dot in the plots represents one animal and significance of mean differences between the groups was assessed 
using Tukey’s HSD. Asterisks indicate significance: *P < 0.05, **P < 0.01, ***P < 0.001.
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These results indicate that Nogo-A neutralization leads to the formation of a more mature vascular network 
and may prevent immature blood vessel formation caused by sole VEGF treatment. Conclusively, the study sug-
gests that Nogo-A targeted therapy might represent a safe and effective alternative to VEGF treatment in terms of 
promoting vascular repair without the risk of blood brain barrier disruption following cerebral ischemia.
Discussion
Angiogenesis and repair of the compromised vasculature in the stroke affected CNS tissue is a promising ther-
apeutic target for post-stroke recovery. However, the clinical usability of vascular growth factors to promote 
revascularization of the ischemic tissue is compromised by the BBB destabilizing effects of VEGFs, which lead 
to enhanced edema and raise the risk of hemorrhagic transformation. In this study, we pursued an alternative 
strategy to enhance vascular repair by targeting the growth inhibitory protein Nogo-A. We demonstrate that 
antibody-mediated neutralization of Nogo-A protects the adult vasculature against leakage during the recov-
ery phase after stroke while promoting vascular repair in the peri-infarct region. In particular, we show that 1) 
Nogo-A neutralization and VEGF treatment display equivalent pro-angiogenic effects by increasing vascular 
density in the peri-infarct regions; and 2) that newly formed vessels after Nogo-A neutralization are mature and 
do not show enhanced leakage as opposed to VEGF. Overall, this study identifies Nogo-A antibodies as a new and 
safe therapeutic agent to enhance angiogenesis following ischemic stroke.
Pro-angiogenic therapeutics have attracted increasing attention in the field of CNS ischemia. In particular, 
VEGF is well known for its prominent role in angiogenesis; however, VEGF therapy has failed to meet its prom-
ising expectations mainly due to safety concerns5,20,21. Our study supports these findings and shows that intrac-
erebroventricular administration of recombinant VEGF for 7 days following a focal cortical stroke exacerbates 
Figure 4. Spatial distribution of Evans Blue in cortical brain sections. (A) Schematic overview of regions of 
interest: 1) stroke core (red), proximal and distal peri-infarct regions (yellow), and contralesional site (green). 
Fluorescence intensities along the injured cortex are represented. Blood vessels are visualized by CD31 (red) 
immunostaining and leakage is visualized by EB fluorescence (blue). Scale bar = 50 μm (B) Relative EB signal 
intensities of the different treatment groups along the injured cortex (C) Quantitative evaluation of EB signal 
intensities as area under the curve. Data are represented as mean ± SD. Differences between the groups were 
assessed using Tukey’s HSD. Asterisks indicate significance: *P < 0.05, **P < 0.01, ***P < 0.001.
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vascular leakage, along with a prominent angiogenic effect. Besides its neuroprotective and pro-angiogenic 
effects5,22, VEGF has been previously shown to disrupt vascular barrier function and promote edema 
development5,20,21. Furthermore, newly formed VEGF-induced blood vessel sprouts are leaky and enhance 
inflammatory processes in the peri-infarct region. The decreased vessel stabilization has been linked to VEGFR2 
activation leading to internalization of tight junction proteins (e.g. VE-cadherins) and loosening of endothelial 
cell contacts in vitro and in vivo23. Moreover, VEGF treatment may lead to pericyte ablation and inhibition of 
vascular smooth muscle function24. These detrimental effects have also been observed in other major ischemic 
conditions including myocardial infarction and retinal ischemia25,26. Consequently, VEGF treatment following 
ischemia raises considerable safety concerns and thus has not been implemented in human trials.
One key mechanism for VEGF-induced hyperpermeability is the RhoA/ROCK pathway; Rho kinase activity 
has strong barrier-disruptive effects and has been associated with increased VEGF levels following ischemia27. 
Interestingly, the vascular growth inhibitory signaling of Nogo-A via its receptor S1PR2 has been shown to also 
activate the RhoA/ROCK pathway12,28. Consequently, antibody-mediated inactivation of Nogo-A signaling may 
directly decrease RhoA levels in stroked tissue and contribute to the vascular integrity. Genetic and pharmaco-
logical blockage of S1PR2 reduced the neurovascular injury and permeability in experimental stroke29; previ-
ous work from our group confirmed these results18. The reduction of leakage following anti-Nogo-A antibody 
treatment may be a consequence of the higher number of pericytes and tight junctions in the vasculature of the 
peri-infarct region observed in our study. Interestingly, co-delivery of VEGF and anti-Nogo-A antibodies also 
reduced vascular hyperpermeability in the peri-infarct region and in part improved the maturation of the vas-
culature. However, it remains unclear if this is mediated through the Rock/RhoA pathway. Future studies may 
address the underlying mechanism between Nogo-A and VEGF following stroke and elucidate how anti-Nogo-A 
antibodies stabilize the microvasculature. Interestingly, the pro-angiogenic effects in the combined treatment 
group were not enhanced compared to the single treatment groups of VEGF or anti-Nogo-A antibodies alone. 
However, it is unclear whether this is due to intrinsic regulatory mechanisms that may inhibit excessive levels of 
angiogenesis or a consequence of the interaction between both substances.
A limitation of the study is the usage of end point measures and the photothrombotic stroke model. We can-
not distinguish if the enhanced Evans blue signals in due to the damaged peri-infarct vasculature caused by the 
initial stroke injury or rather reflects the leakiness of newly formed and immature blood vessels. Dissecting these 
mechanisms is however, difficult and might be addressed in future studies with advancements in genetic models 
and in vivo microscopy.
Apart from Nogo-A, guidance molecule targeted therapies have been previously shown to act on both vascu-
lar repair and permeability following stroke. For example, Semaphorin 3A has been shown to suppress periph-
eral and CNS angiogenesis and to act as an important vascular permeability factor independent of VEGF30,31. 
Moreover, ephrinA1- EphA2 signaling has important roles in maintaining tight junction formation and its mis-
regulation has been linked to BBB disruption32. Since it is known that genetic deletion of Nogo-A may change 
expression of other guidance molecules33, we cannot exclude that such indirect effects may also contribute to the 
reduced vascular leakage in anti-Nogo-A antibody treated animals.
Figure 5. Maturation and tight junction composition of the endothelium in the ischemic border zone.  
(A) Schematic composition of blood brain barrier with the vasculature, pericytes, astrocyte end feet, neurons 
and the tight junction proteins (VE-Cadherin, ZO-1, Claudin-5). (B) Fluorescence images of the vascular 
endothelium with pericytes (CD13) and tight junction proteins (ZO-1 and VE-Cadherin). Scale bar = 5 µm.  
(C) Quantitative assessment of endothelial coverage with pericytes and tight junction proteins in the peri-
infarct region. Data are represented as mean ± SD. Differences between the groups were assessed using Tukey’s 
HSD. Asterisks indicate significance: *P < 0.05, **P < 0.01, ***P < 0.001.
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Taken together, the administration of anti-Nogo-A antibodies may represent a new, promising, and safe ther-
apeutic strategy to enhance angiogenesis, prevent vascular leakage and retain tissue integrity and functionality in 
the peri-infarct zone following ischemic stroke. Safety and feasibility of intrathecal anti-Nogo-A antibody deliv-
ery have recently been demonstrated in a phase I clinical trial for spinal cord injury34.
Methods
Experimental design. The goal of the present study was to test the angiogenic potential and safety of intrac-
erebroventricularly applied anti-Nogo-A antibodies in mice with cerebral ischemia. We hypothesized that 1) 
pro-angiogenic effects caused by neutralization of Nogo-A are comparable to those exerted by VEGF and that 2) 
Nogo-A neutralization will not enhance vascular leakage when administered in the acute phase of an ischemic 
stroke unlike VEGF; thus making it a more suitable candidate for therapeutic angiogenesis following cerebral 
ischemia.
To evaluate the evolution of BBB opening following ischemic injury, we performed a time-course study. BBB 
opening was assessed at 1 day (N = 6), 7 days (N = 6) and 21 days (N = 10) after photothrombotic stroke; Evans 
blue i.v. was used as indicator of BBB permeability. Based on these findings and previous observations, we decided 
to assess vascular repair and permeability at 10 days following injury. Stroked mice received a continuous infu-
sion of either VEGF (N = 7), anti-Nogo-A antibodies (N = 5), a combination of both (VEGF+ anti-Nogo-A Ab, 
N = 7) or a control antibody (N = 6) for seven consecutive days. The nucleotide analogue EdU was injected to 
detect newly formed blood vessels at day 6–8. One day before perfusion, animals were systemically injected with 
Evans blue. To characterize the loss of BBB integrity after stroke, we histologically and spectrophotometrically 
analyzed affected ischemic brain tissue. The mortality rate during the stroke surgeries was as expected at 5% in 
total. For the time course experiment mortality was 0% (0/22); during the BBB permeability experiment between 
Ctrl Ab, VEGF, a-Ng-A ab, combined, we observed a mortality of 3/28 animals: 2 animals died that received 
a-Ng-A ab, 1 animal died that received Ctrl-Ab. All animals are presented in the study; no statistical outliers were 
excluded. Data was acquired blinded.
Animals. All animal experiments were performed in accordance with governmental, institutional (University 
of Zurich), and ARRIVE guidelines and had been approved by the Cantonal Veterinary Department of Zurich. 
Adult male wildtype mice (10–14 weeks) of the C57BL/6 strain (16–25 g) were used. Pilot experiments in adult 
female mice did not show any gender-specific differences (data not shown). Mice were housed in standard Type 
II/III cages at least in pairs in a temperature and humidity controlled room with a constant 12/12 h light/dark 
cycle (light on from 6:00 a.m. until 6:00 p.m.).
Photothrombotic stroke and angiogenic treatment. Animals were deeply anesthetized with 5% iso-
flurane (Attane, Provet AG) in a transparent induction chamber. Stroke surgery was performed under 2–3% 
isoflurane. A photothrombotic stroke to unilaterally lesion the sensorimotor cortex was induced on the right hem-
isphere, as previously described35. Briefly, animals were fixed in a stereotactic frame (David Kopf Instruments) 
and the skull was exposed through a midline skin incision. A cold light source (Olympus KL 1500LCS, 150 W, 
3000 K) was positioned over the right forebrain cortex at anterior/posterior: −1.5 mm to +1.5 mm and medial/
lateral 0 mm to +2 mm relative to Bregma. Rose Bengal (10 mg/ml, in 0.9% NaCl, Sigma) was injected intra-
peritoneally 5 minutes prior to illumination. Subsequently, the exposed area was illuminated through the intact 
skull. After 8.5 minutes of illumination, light exposure was stopped. For postoperative care, all animals received 
analgesics (Novalgin, Sanofi) for at least 3 days after surgery.
For constant delivery of antibodies and growth factors, mice were randomly assigned to 4 groups and 
received: 1) 10 μg/ml recombinant human VEGF165 (R&D Systems) (N = 7); 2) 7 mg/ml Ig G1 mouse monoclonal 
anti-Nogo-A antibody 11C7 (Novartis) (N = 5); (3) combinational 10 μg/ml VEGF and 7 mg/ml anti-Nogo-A 
Ab (n = 7); or (4) 7 mg/ml of the control antibody Ig G1 isotype FG12 (n = 6) through implanted mini-osmotic 
pumps for 7 consecutive days (Alzet Model 107D, Alzet Brain Infusion Kit 3). The concentrations were chosen 
based on previous studies23,24. The cannula of the pump was inserted into the left ventricle (anterior/posterior 
−0.57 mm, medial/lateral −1.5 mm, dorsal/ventral −2.1 mm to Bregma). The osmotic pump was placed in the 
midscapula region to permit free head and neck movement. Although the osmotic pump begins operating imme-
diately, we adapted the set-up to allow a 24 h delay of the application. This was achieved by filling the tip of the 
catheter with a control solution (0.9% saline) according to the manufacturer’s recommendations.
EdU application. In order to identify proliferating endothelial cells, the animals received three consecutive 
i.p. injections of 5-ethynyl-2′-deoxyuridine (EdU, Sigma) at a dose of 50 mg/kg on day 6, 7 and 8 after stroke. 
EdU was detected using the Click-iT EdU Alexa Fluor 647 Imaging kit (Thermo Fisher Scientific) according to 
the manufacturer’s protocol. Endothelial cells (CD31+) incorporating EdU were considered as newly formed 
following stroke.
Tissue processing. Mice were deeply anesthetized by intraperitoneal injection of pentobarbital (150 mg/kg 
body weight, Streuli Pharma AG). Animals were perfused with isotonic Ringer solution (containing 5 ml/l 
Heparin, B. Braun) followed by paraformaldehyde (PFA, 4%, in 0.2 M phosphate buffer, pH 7). For immunohis-
tological analysis, brains were removed and 4 h post-fixed in 4% PFA, transferred to 30% sucrose for cryoprotec-
tion and stored at 4 °C. Coronal sections with a thickness of 40 µm were cut using a sliding microtome (Microm 
HM430, Leica). Sections were collected and stored as free-floating sections in cryoprotectant solution at −20 °C 
until further processing. For spectrophotometric analysis of CNS tissue was isolated and stored at −20 °C before 
further processing.
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Immunohistochemistry. For immunohistochemistry, brain sections were washed with 0.1 M phosphate 
buffer (PB) and then incubated for 30 minutes at room temperature in a blocking solution containing TNB, TBST 
(0.1%) and normal goat serum (3%). For detection of vascular endothelial cells, sections were incubated overnight 
at 4 °C with monoclonal rat anti-CD31 antibody (BD Biosciences, 1:50). Tight junction proteins were detected 
with the following antibodies: mouse anti-Claudin-5 antibody (1:200, ThermoFischer); rat anti-VE-Cadherin 
antibody (1:100, ThermoFischer) and rabbit anti-ZO-1 antibody (1:100, ThermoFischer). Pericytes were visu-
alized with goat anti-CD13 (1:200; R&D). The primary antibody incubation was followed by 2 h incubation at 
room temperature with corresponding fluorescence secondary antibodies (1:500, ThermoFisher). DAPI (1:2000 
in 0.1 M PB, Sigma) was used to visualize nuclei. Sections were mounted in 0.1 M PB on Superfrost PlusTM 
microscope slides and coverslipped using Mowiol.
Evans Blue quantification to assess systemic leakage. EB dye is an inert tracer commonly used for 
investigations of vascular permeability in animal models. EB dye binds to serum albumin. Since serum albumin 
does not cross the BBB under normal physiological conditions, spectrophotometric determination of EB dye 
accumulation in brain tissue outside blood vessels reflects the extent of vascular leakage.
Tissue samples, which were collected as previously described, were homogenized in lysis buffer (250 μl/mg 
tissue weight; Tris-HCl, EDTA, NP-40, NaCl, protease inhibitor cocktail) and incubated for 2 hours at 4 °C, shack-
ing. The mixture was centrifuged to remove precipitated fragments (25 min, 15000 g, 4 °C) and the extracted 
supernatant was collected in a 96-well plate. The EB concentrations were measured at 620 nm using a standard 
microplate reader (Spark, Tecan) and quantified against a standard curve. The results were expressed as micro-
grams of EB per milligram of brain tissue.
Fluorescence microscopy and quantification. Imaging of brain sections 10 days after stroke was per-
formed with an Axio Scan.Z1 slide scanner (Zeiss) and an Olympus FV1000 laser scanning confocal microscope 
equipped with 10×, 20× and 40× objectives. Images were processed using Fiji (ImageJ) and Adobe Illustrator 
CS6. First, stroke sizes were compared between animals in 40 μm coronal sections stained with fluorescent 
NeuroTrace (1:500, ThermoFischer) and DAPI (1:2000, Sigma). Brain sections at sic defined landmarks (2.5, 1.5, 
0.5, −0.5, −1.5, −2.5 mm in relation to bregma) were analyzed for depth of the cortical lesion. The dorso-ventral, 
medio-lateral, and anterior-posterior stroke extent was then used to modulate a precise ellipsoid with the coor-
dinates relative to Bregma.
All other analysis steps were performed in the same region of interest (ROI), a peri-infarct region distal to the 
stroke core with a width of 300 μm. To assess post-stroke angiogenesis an ImageJ (Fiji) script was established to 
automatically calculate (1) area fraction of blood vessels, (2) number of blood vessels, (3) number of branches and 
junctions, (4) distance between blood vessels and (5) vessel distribution36.
Statistical analysis. Statistical analysis was performed using RStudio. Sample sizes were designed with ade-
quate power according to our previous studies and to the literature. All data were tested for normal distribution 
by using the Shapiro-Wilk test. Multiple Normally distributed data were tested for differences with a two-tailed 
unpaired one-sample t-test to compare differences between two groups. Non-normally distributed data were 
tested with a Mann-Whitney U test. Multiple comparisons were initially tested for normal distribution with the 
Shapiro-Wilk test. The significance of mean differences between normally distributed multiple comparisons was 
assessed using Tukey’s HSD. Non-normally distributed multiple comparison data were tested by Dunn’s test. Data 
are expressed as mean ± SD and statistical significance was defined as *p < 0.05, **p < 0.01, and ***p < 0.001.
Data availability
All raw data is available upon request.
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